The US pharmaceutical landscape is in the midst of impactful shifts. A series of ambitious, aggressive, and often interconnected federal policy changes—from direct drug price controls and sweeping Pharmacy Benefit Manager reforms to strategic initiatives to reshore manufacturing and rapidly evolving FDA approaches—is creating a new reality for industry leaders, innovators, and strategists. In this analysis, a federal policy expert unpacks the complex forces reshaping how life-saving therapies are researched, developed, manufactured, and delivered.
Key Features
•Understand the Interconnectedness of U.S. Federal Policies.
•Analyze the Strategic Impacts of Key Legislation and Executive Actions.
•Evaluate Challenges and Opportunities in a Dynamic Regulatory Environment.
•Analyze the Interplay of U.S. Federal Actions and Industry Operations.
•Formulate Adaptive Strategies for Industry Resilience.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Molly Klote, MD, is the former Director of the US Department of Health and Human Services Office for Human Research Protections (OHRP). OHRP is the policy, education, and compliance office that oversees federally funded medical research for 21 federal agencies, 13,000 institutions, and over 6000 institutional review boards in the US and internationally. It is the proponent office for the policy that is called "The Common Rule" (45 CFR 46). Before joining OHRP, Dr. Klote spent six years as the research policy, regulatory, and education lead for the Veterans Health Administration, the largest integrated healthcare system in the United States. Prior to the Veterans Health Administration, she served for 30 years in the Army, with her final assignment at the rank of Colonel, working for the Army Surgeon General overseeing all US Army Human Research policy and compliance. Additionally, Dr. Klote has directed two major research program offices, served as an Institutional Official, chaired three Institutional Review Boards, and led a Research Scientific Review Board.
She recently launched her own consulting company, Klote Medical Research Advisors, LLC, to bring her over 36 years of distinguished military and civilian federal experience to those who need to better understand federal research policy.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vos droits au titre de la garantie légale : Chaque consommateur de l'UE bénéficie d'au moins deux ans de protection au titre de la garantie légale pour tout bien de consommation vendu dans l'UE. Voir plus
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Paperback. Etat : new. Paperback. The US pharmaceutical landscape is in the midst of impactful shifts. A series of ambitious, aggressive, and often interconnected federal policy changesfrom direct drug price controls and sweeping Pharmacy Benefit Manager reforms to strategic initiatives to reshore manufacturing and rapidly evolving FDA approachesis creating a new reality for industry leaders, innovators, and strategists. In this analysis, a federal policy expert unpacks the complex forces reshaping how life-saving therapies are researched, developed, manufactured, and delivered.Key FeaturesUnderstand the Interconnectedness of U.S. Federal Policies.Analyze the Strategic Impacts of Key Legislation and Executive Actions.Evaluate Challenges and Opportunities in a Dynamic Regulatory Environment.Analyze the Interplay of U.S. Federal Actions and Industry Operations.Formulate Adaptive Strategies for Industry Resilience. The US pharmaceutical landscape is in the midst of impactful shifts. In this analysis, a federal policy expert unpacks the complex forces reshaping how life-saving therapies are researched, developed, manufactured, and delivered. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9781041159803
Quantité disponible : 1 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 50697592
Quantité disponible : 10 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 50697592-n
Quantité disponible : 10 disponible(s)
Vendeur : BargainBookStores, Grand Rapids, MI, Etats-Unis
Paperback or Softback. Etat : New. Adapting to Change: Federal Policy Dynamics and the Pharmaceutical Industry. Book. N° de réf. du vendeur BBS-9781041159803
Quantité disponible : 5 disponible(s)
Vendeur : Chiron Media, Wallingford, Royaume-Uni
PF. Etat : New. This item is printed on demand. Brand new book, sourced directly from publisher. Dispatch time is 6-7 days from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely. N° de réf. du vendeur 6666-IUK-9781041159803
Quantité disponible : 20 disponible(s)
Vendeur : PBShop.store US, Wood Dale, IL, Etats-Unis
PAP. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L0-9781041159803
Quantité disponible : Plus de 20 disponibles
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. N° de réf. du vendeur I-9781041159803
Quantité disponible : Plus de 20 disponibles
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. N° de réf. du vendeur 408602162
Quantité disponible : 3 disponible(s)
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
PAP. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L0-9781041159803
Quantité disponible : Plus de 20 disponibles
Vendeur : Rarewaves.com USA, London, LONDO, Royaume-Uni
Paperback. Etat : New. The US pharmaceutical landscape is in the midst of impactful shifts. A series of ambitious, aggressive, and often interconnected federal policy changes-from direct drug price controls and sweeping Pharmacy Benefit Manager reforms to strategic initiatives to reshore manufacturing and rapidly evolving FDA approaches-is creating a new reality for industry leaders, innovators, and strategists. In this analysis, a federal policy expert unpacks the complex forces reshaping how life-saving therapies are researched, developed, manufactured, and delivered.Key Features.Understand the Interconnectedness of U.S. Federal Policies.Analyze the Strategic Impacts of Key Legislation and Executive Actions.Evaluate Challenges and Opportunities in a Dynamic Regulatory Environment.Analyze the Interplay of U.S. Federal Actions and Industry Operations.Formulate Adaptive Strategies for Industry Resilience. N° de réf. du vendeur LU-9781041159803
Quantité disponible : Plus de 20 disponibles